ArticleUltrasonography (Seoul, Korea)2026
Monitoring of low-risk pancreatic cystic lesions with targeted abdominal ultrasound: diagnostic yield, clinical utility, and acceptance.
Article in Ultrasonography (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transabdominal ultrasonography as an alternative modality for pancreatic cyst surveillance: potentials and limitations.Ultrasonography (Seoul, Korea) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate the utility of targeted abdominal ultrasound (TAUS) for follow-up of low-risk pancreatic cystic lesions (PCLs), assessing diagnostic performance, agreement with advanced imaging, patient acceptance, clinical usefulness, and contribution of structured reporting.
methodsThis prospective study included 120 patients with low-risk PCLs previously characterized by magnetic resonance cholangiopancreatography or endoscopic ultrasound. TAUS was performed using a wideband convex matrix probe (1.8-6.2 MHz) and a structured protocol documenting lesion location, size, morphology (septa, mural nodules), and relation to the main pancreatic duct. Contrast-enhanced ultrasound (CEUS) was used in selected cases. Outcomes included agreement with reference imaging (intraclass correlation coefficient [ICC]), patient preference, and perceived usefulness.
resultsTAUS enabled complete pancreatic visualization in 80.0% of patients and overall detection rate in 88.3%. Detection varied by location (P=0.028), highest in the body (94.5%) and lowest in the tail (68.0%). Agreement for maximal cyst diameter was excellent (ICC, 0.98; 95% confidence interval, 0.971 to 0.986), with 90.8% of measurements within ±20% of the reference modality. When B-mode was suboptimal, CEUS was used in 2.5% of cases and improved delineation of architecture (mural nodules, septations). Limitations included low detection of multifocal disease (11.1%) and restricted assessment of ductal communication (46.6%). TAUS was clinically useful in 78.0% and preferred by patients when characterization was adequate (88.3%).
conclusionTAUS is a promising noninvasive imaging tool for monitoring low-risk PCLs in favorable acoustic windows, showing high diagnostic accuracy, excellent agreement with advanced imaging, and strong patient acceptance. Its diagnostic performance is limited in multifocal, complex, or tail-located lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.